Latest Conference Articles

Breast Cancer Testing May Benefit from the Multi-Omics Approach Over Biomarker Assessment Alone

Breast Cancer Testing May Benefit from the Multi-Omics Approach Over Biomarker Assessment Alone

April 13th 2021, 2:45pm

AACR Annual Meeting

For patients with metastatic breast cancer, research suggests that utilizing a multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data may be feasible and better than DNA sequencing alone.

Telisotuzumab Vedotin Shows Promising Efficacy and Safety Results for c-Met+ NSCLC

Telisotuzumab Vedotin Shows Promising Efficacy and Safety Results for c-Met+ NSCLC

April 13th 2021, 1:45am

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.

D-0316 Shows Clinically Meaningful Improvement in Patients with T790M+ and EGFR+ NSCLC

D-0316 Shows Clinically Meaningful Improvement in Patients with T790M+ and EGFR+ NSCLC

April 12th 2021, 11:00pm

More than half of patients with T790M-positive non-small cell lung cancer had a response to the third generation EGFR TKI D-0316 in a phase 2 study.

Lifileucel TIL Therapy Demonstrates Durable Responses in Pretreated Advanced Melanoma

Lifileucel TIL Therapy Demonstrates Durable Responses in Pretreated Advanced Melanoma

April 11th 2021, 1:00pm

AACR Annual Meeting

In the phase 2 C-144-01 trial, patients had durable responses to treatment with the tumor-infiltrating lymphocyte lifileucel after more than 28 months of follow-up.

HER2-Expressing Gastric Cancer Cells Respond to Treatment With Trastuzumab Deruxtecan

HER2-Expressing Gastric Cancer Cells Respond to Treatment With Trastuzumab Deruxtecan

April 10th 2021, 7:30pm

AACR Annual Meeting

For the treatment of patients with HER2-amplified gastric cancers in addition to those with HER2 moderate-, low-, and non-expressing disease, trastuzumab deruxtecan has shown to be an effective therapeutic option.

Zenocutuzumab Effectively Blocks Growth of NRG1 Fusion-Driven Tumors

Zenocutuzumab Effectively Blocks Growth of NRG1 Fusion-Driven Tumors

April 10th 2021, 6:00pm

AACR Annual Meeting

In NRG1 fusion–positive cell lines, zenocutuzumab demonstrated blockage of growth and cell death, as well as tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.

Voruciclib Demonstrates Preliminary Activity Alone or in Combination with Sotorasib or Adagrasib in KRAS+ Cancers

Voruciclib Demonstrates Preliminary Activity Alone or in Combination with Sotorasib or Adagrasib in KRAS+ Cancers

April 10th 2021, 5:30pm

AACR Annual Meeting

In preclinical models of KRAS-mutant cancer, voruciclib, a CDK9 inhibitor, showed early activity as monotherapy and when used in combination with sotorasib and adagrasib, according to findings presented during Week 1 of the 2021 AACR Annual Meeting.

Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma

Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma

April 10th 2021, 12:30pm

AACR Annual Meeting

In patient with metastatic uveal melanoma, frontline treatment with tebentafusp achieved significant and clinically meaningful improvement in overall survival, according to data from the phase 3 IMCgp100-202 trial.

Copanlisib Plus Rituximab Extends Progression-Free Survival in Indolent NHL

Copanlisib Plus Rituximab Extends Progression-Free Survival in Indolent NHL

April 10th 2021, 12:30pm

AACR Annual Meeting

Primary results from the phase 3 CHRONOS-3 study revealed a survival benefit with the combination of copanlisib in combination with rituximab over rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

Men With High Genetic Risk of Lethal Prostate Cancer May Lower Their Risk With a Healthier Lifestyle

Men With High Genetic Risk of Lethal Prostate Cancer May Lower Their Risk With a Healthier Lifestyle

April 10th 2021, 12:30pm

According to new research presented during the virtual AACR Annual Meeting 2021, the likelihood of developing metastatic disease or dying of prostate cancer among men with high genetic risk was lowered in men who maintained a healthy lifestyle.